ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Recommendation of “Buy” by Analysts

ICU Medical, Inc. (NASDAQ:ICUI) has been given an average rating of “Buy” by the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $168.40.

Several research firms recently commented on ICUI. Weiss Ratings upgraded ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Sanford C. Bernstein lowered shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th. BTIG Research assumed coverage on shares of ICU Medical in a research note on Monday, June 15th. They issued a “buy” rating and a $170.00 target price for the company. Finally, Piper Sandler cut their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a report on Friday, April 17th.

Insider Transactions at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. The trade was a 11.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director David C. Greenberg sold 2,424 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director directly owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

A number of large investors have recently modified their holdings of the business. Bank of America Corp DE lifted its position in ICU Medical by 11.2% during the first quarter. Bank of America Corp DE now owns 331,739 shares of the medical instruments supplier’s stock valued at $42,844,000 after purchasing an additional 33,508 shares during the last quarter. Edgestream Partners L.P. bought a new position in ICU Medical in the first quarter valued at $965,000. Janus Henderson Group PLC boosted its holdings in shares of ICU Medical by 3.9% in the 1st quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock worth $345,607,000 after purchasing an additional 99,256 shares in the last quarter. Amundi raised its stake in shares of ICU Medical by 39.9% during the first quarter. Amundi now owns 6,475 shares of the medical instruments supplier’s stock worth $836,000 after acquiring an additional 1,848 shares in the last quarter. Finally, California State Teachers Retirement System lifted its stake in ICU Medical by 25.2% in the first quarter. California State Teachers Retirement System now owns 27,512 shares of the medical instruments supplier’s stock worth $3,553,000 after purchasing an additional 5,536 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $148.46 on Friday. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. The stock’s fifty day simple moving average is $132.62 and its two-hundred day simple moving average is $138.43. ICU Medical has a 1-year low of $107.00 and a 1-year high of $160.29. The stock has a market cap of $3.71 billion, a PE ratio of 80.25, a price-to-earnings-growth ratio of 2.05 and a beta of 0.76.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The firm had revenue of $525.77 million for the quarter, compared to the consensus estimate of $520.65 million. During the same period in the previous year, the firm earned $1.72 EPS. The business’s revenue for the quarter was down 12.3% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, analysts forecast that ICU Medical will post 6.5 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.